儿童口服抗凝剂的临床经验。
Clinical experience with an oral anticoagulant in children.
作者信息
Carpentieri U, Nghiem Q X, Harris L C
出版信息
Arch Dis Child. 1976 Jun;51(6):445-8. doi: 10.1136/adc.51.6.445.
Abstract
Nineteen cardiac patients were given warfarin sodium to prevent thrombosis and embolism. Empirical dosage resulted in long hospital stays to obtain a stable therapeutic prothrombin time. Using a dosage of 0 therefore 5-0 therefore 7 mg/kg, therapeutic levels were achieved in a much shorter time. When prothrombin time was excessive, it was successfully reduced with vitamin K or plasma. A haematoma in one case and haematuria in another were easily controlled. Warfarin sodium appears to be appropriate and effective for children requiring anticoagulants within the above dosage limits and with meticulous follow-up.
摘要
19名心脏病患者接受了华法林钠治疗以预防血栓形成和栓塞。经验性剂量导致住院时间延长以获得稳定的治疗性凝血酶原时间。使用0.5-0.7mg/kg的剂量，可在更短的时间内达到治疗水平。当凝血酶原时间过长时，使用维生素K或血浆可成功使其降低。1例出现血肿，另1例出现血尿，均易于控制。对于在上述剂量范围内需要抗凝剂并进行细致随访的儿童，华法林钠似乎是合适且有效的。
相似文献
1
Clinical experience with an oral anticoagulant in children.儿童口服抗凝剂的临床经验。
Arch Dis Child. 1976 Jun;51(6):445-8. doi: 10.1136/adc.51.6.445.
2
Oral anticoagulants in clinical practice.临床实践中的口服抗凝剂。
Semin Hematol. 1978 Jan;15(1):27-34.
3
Oral anticoagulant prophylaxis and epidural catheter removal.口服抗凝剂预防与硬膜外导管拔除
Reg Anesth. 1996 Nov-Dec;21(6):517-24.
4
Role of anticoagulants in preventing embolization from prosthetic heart valves.
JAMA. 1967 Oct 23;202(4):282-6.
5
Secondary prophylaxis of venous thromboembolism: rational use of oral anticoagulants.
Haematologica. 1995 Mar-Apr;80(2 Suppl):87-91.
6
Use of artificial neural network to predict warfarin individualized dosage regime in Chinese patients receiving low-intensity anticoagulation after heart valve replacement.使用人工神经网络预测心脏瓣膜置换术后接受低强度抗凝治疗的中国患者的华法林个体化给药方案。
Int J Cardiol. 2014 Oct 20;176(3):1462-4. doi: 10.1016/j.ijcard.2014.08.062. Epub 2014 Aug 17.
7
A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.对于高血栓栓塞风险患者，在侵入性操作中持续使用剂量降低的华法林的可行性研究。
Chest. 2005 Mar;127(3):922-7. doi: 10.1378/chest.127.3.922.
8
An audit of anticoagulation and endocarditis prophylaxis after heart valve surgery.
N Z Med J. 1991 Mar 13;104(907):85-8.
9
Anticoagulant management of pregnant women with mechanical heart valve replacement during perioperative period.围手术期机械心脏瓣膜置换术后孕妇的抗凝管理
Arch Gynecol Obstet. 2016 Jan;293(1):69-74. doi: 10.1007/s00404-015-3768-0. Epub 2015 Jun 6.
10
Low-dose oral anticoagulation and antiplatelet therapy with St. Jude Medical heart valve prosthesis.使用圣犹达医疗心脏瓣膜假体的低剂量口服抗凝和抗血小板治疗。
J Heart Valve Dis. 1999 Nov;8(6):665-73.
引用本文的文献
1
Antidotes to coumarins, isoniazid, methotrexate and thyroxine, toxins that work via metabolic processes.香豆素、异烟肼、甲氨蝶呤和甲状腺素的解毒剂，这些毒素通过代谢过程起作用。
Br J Clin Pharmacol. 2016 Mar;81(3):437-45. doi: 10.1111/bcp.12736. Epub 2015 Oct 24.
2
Anticoagulant therapy in pediatrics.儿科抗凝治疗
J Basic Clin Pharm. 2014 Mar;5(2):27-33. doi: 10.4103/0976-0105.134947.
3
Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.新生儿和儿童的抗血栓治疗：抗血栓治疗和血栓预防，第 9 版：美国胸科医师学会基于证据的临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e737S-e801S. doi: 10.1378/chest.11-2308.
4
Oral anticoagulants in pediatric cardiac practice: A systematic review of the literature.儿科心脏科实践中的口服抗凝剂：文献系统综述
Ann Pediatr Cardiol. 2010 Jan;3(1):31-4. doi: 10.4103/0974-2069.64371.
5
Anticoagulation and thrombolysis in children.儿童抗凝与溶栓治疗
Tex Heart Inst J. 1992;19(3):168-77.
6
Anticoagulation therapy in children.儿童抗凝治疗
Paediatr Drugs. 2003;5(12):803-20. doi: 10.2165/00148581-200305120-00004.
7
Oral anticoagulation in paediatric patients: dose requirements and complications.儿科患者的口服抗凝治疗：剂量需求与并发症
Arch Dis Child. 1996 Mar;74(3):228-31. doi: 10.1136/adc.74.3.228.
8
Hemostatic complications in renal disorders of the young.青少年肾脏疾病中的止血并发症。
Pediatr Nephrol. 1996 Feb;10(1):88-99. doi: 10.1007/BF00863459.
本文引用的文献
1
Anticoagulant therapy with coumarin congeners. Action and guidelines.
Am J Med. 1962 Nov;33:679-91. doi: 10.1016/0002-9343(62)90246-2.
2
Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.抗凝药物治疗肺栓塞的对照试验。
Lancet. 1960 Jun 18;1(7138):1309-12. doi: 10.1016/s0140-6736(60)92299-6.
3
Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose.香豆素类抗凝药物的研究。不采用负荷剂量起始华法林治疗。
Circulation. 1968 Jul;38(1):169-77. doi: 10.1161/01.cir.38.1.169.
4
Potentiation of anticoagulant effect of warfarin by phenylbutazone.保泰松对华法林抗凝作用的增强作用。
N Engl J Med. 1967 Mar 2;276(9):496-501. doi: 10.1056/NEJM196703022760904.
5
Interaction of commonly prescribed drugs and warfarin.
Ann Intern Med. 1970 Jun;72(6):853-6. doi: 10.7326/0003-4819-72-6-853.
6
Coumarin drug interactions.香豆素类药物相互作用。
Mayo Clin Proc. 1970 Apr;45(4):249-55.
7
The pharmacological basis of oral anticoagulant therapy.
Thromb Diath Haemorrh Suppl. 1966;21:227-56.
8
Determinants of the response to oral anticoagulant drugs in man.人体口服抗凝药物反应的决定因素。
Pharmacol Rev. 1970 Mar;22(1):35-96.
9
Warfarin therapy. 2.
N Engl J Med. 1970 Oct 8;283(15):801-3. doi: 10.1056/NEJM197010082831508.
10
Recent developments in antithrombotic therapy.
Ann Intern Med. 1969 Oct;71(4):823-31. doi: 10.7326/0003-4819-71-4-823.
Zotero 插件